Exelixis (EXEL) Cash from Investing Activities Growth (3y) (2013 - 2026)
Exelixis (EXEL) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
- |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
116.52% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
- |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
38.24% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Exelixis |
13.61 Bn |
12.83 Bn |
590.86 Mn |
-0.98% |
| Date | Value |
|---|
| Apr 3, 2026 |
-0.98% |
| Jan 2, 2026 |
28.28% |
| Oct 3, 2025 |
33.30% |
| Jul 4, 2025 |
56.53% |
| Apr 4, 2025 |
38.69% |
| Jan 3, 2025 |
-92.55% |
| Sep 27, 2024 |
-117.04% |
| Jun 28, 2024 |
46.66% |
| Mar 29, 2024 |
21.55% |
| Dec 29, 2023 |
-42.56% |
| Mar 31, 2023 |
-52.12% |
| Sep 30, 2022 |
30.62% |
| Jul 1, 2022 |
1.85% |
| Apr 1, 2022 |
11.53% |
| Dec 31, 2021 |
54.95% |
| Oct 1, 2021 |
30.49% |
| Jul 2, 2021 |
-2.25% |
| Apr 2, 2021 |
64.34% |
| Jan 1, 2021 |
170.41% |
| Apr 3, 2020 |
-1.85% |
